SCHEMBL1128719

SCHEMBL1128719

CC(=O)CC(=O)Nc1ccc(Br)cc1C

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.60
MEN1 O00255 3/20 0.60
KMT2A Q03164 3/20 0.60
CYP1A2 P05177 1/20 0.60
CYP3A4 P08684 1/20 0.60
CYP2D6 P10635 1/20 0.60
CYP2C9 P11712 1/20 0.60
CYP2C19 P33261 1/20 0.60
ALDH1A1 P00352 6/20 0.59
GAA P10253 1/20 0.59
SIGMAR1 Q99720 2/20 0.53
NPY1R P25929 1/20 0.52
NPY2R P49146 1/20 0.52
SMN1; SMN2 Q16637 2/20 0.51
LMNA P02545 1/20 0.51
DHODH Q02127 1/20 0.50
TP53 P04637 1/20 0.49
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
HTT P42858 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27826167 0.87 ALDH1A1 (0.48) MAPTMEN1KMT2ACYP1A2CYP3A4
SCHEMBL30894835 0.87 MAPT (0.60) MAPTMEN1KMT2ACYP1A2CYP3A4
SCHEMBL9416712 0.87 MAPT (0.60) MAPTMEN1KMT2ACYP1A2CYP3A4
SCHEMBL9416772 0.85 ALDH1A1 (0.58) MAPTMEN1KMT2ACYP1A2CYP3A4
SCHEMBL9416690 0.85 ALDH1A1 (0.58) MAPTMEN1KMT2ACYP1A2CYP3A4
SCHEMBL11620459 0.85 MAPT (0.61) MAPTMEN1KMT2ACYP1A2CYP3A4
SCHEMBL10628983 0.84 ALDH1A1 (0.57) MAPTMEN1KMT2ACYP1A2CYP3A4
SCHEMBL9416776 0.84 ALDH1A1 (0.60) MAPTMEN1KMT2ACYP1A2CYP3A4
SCHEMBL29528391 0.83 ALDH1A1 (0.71) MAPTMEN1KMT2ACYP1A2CYP3A4
SCHEMBL7935570 0.83 ALDH1A1 (0.59) MAPTMEN1KMT2ACYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150368278-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2015-12-24 US disclosed
US-8957049-B2 Inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2015-02-17 US disclosed
US-20110172186-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. 2011-07-14 US disclosed
EP-2282742-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE Infinity Pharmaceuticals, Inc. (US) 2011-02-16 EP disclosed
WO-2009126691-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC (US) 2009-10-15 WO disclosed
EP-0096214-B1 ANTIBACTERIAL PYRIMIDINE COMPOUNDS THE WELLCOME FOUNDATION LIMITED (GB) 1991-02-27 EP disclosed
US-4710507-A Quinolone inotropic agents PFIZER INC. (US) 1987-12-01 US disclosed
EP-0148623-A2 Quinolone inotropic agents Pfizer Limited (GB) 1985-07-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172186-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, ASAH1 MAPT 3395/4885MEN1 4220/4885KMT2A 2097/4885
US-20150368278-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, ASAH1 MAPT 3395/4885MEN1 4220/4885KMT2A 2097/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.